VAGINAL MICROBIOME DYSBIOSIS AND RECURRENT BACTERIAL VAGINOSIS: BIOFILM ECOLOGY, CLINICAL EVIDENCE, REALWORLD ANALYTICS AND PRECISION PREVENTION
Keywords:
bacterial vaginosis; recurrent bacterial vaginosis; vaginal dysbiosis; vaginal microbiome; Gardnerella; Fannyhessea vaginae; Lactobacillus crispatus; polymicrobial biofilm; metronidazole; Lactin-V; partner treatment; real-world evidence; machine learning; antimicrobial stewardshipAbstract
Recurrent bacterial vaginosis (BV) constitutes a persistent clinical challenge in which temporary symptom resolution after antimicrobial therapy frequently fails to produce durable microbial recovery. Its pathobiology involves loss of protective lactic-acid producing vaginal communities, expansion of diverse anaerobic organisms, surface-associated polymicrobial structures, host–microbe interactions, and sexual exchange of BV-associated bacteria. Objective: To critically synthesize microbiological and clinical conventional and emerging prevention strategies, and assess the role of real-world evidence (RWE) and computational methods.
Downloads
References
1. Centers for Disease Control and Prevention. Bacterial Vaginosis. Sexually Transmitted Infections Treatment Guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/bv.htm
2. Muzny CA, Sobel JD. Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians. Int J Womens Health. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10423565/
3. Gao M, Manos J, Whiteley G, et al. Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review. J Infect Dis. 2024;230:e508-e517. doi:10.1093/infdis/jiae134.
4. Bacterial Vaginosis—Vaginal Polymicrobial Biofilms and Dysbiosis. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10412922/
5. Cohen CR, Wierzbicki MR, French AL, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020;382:1906-1915. doi:10.1056/NEJMoa1915254.
